CaReMeUK (@caremeuk) 's Twitter Profile
CaReMeUK

@caremeuk

CaReMeUK is a collaboration between national societies to form a Cardio-Renal-Metabolic partnership to improve outcomes in heart, kidney disease and diabetes.

ID: 1440311893793464320

calendar_today21-09-2021 13:49:28

9 Tweet

32 Followers

35 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

๐Ÿ”ฅThe 9th Round of Easy Loan, Earn $40 Reward is in progressโ—๏ธ โฐ Promotion Period: January 15th - Feburary 15th, 2025 ๐Ÿ‘‰ Register now and check more details at gate.io/campaigns/358

๐Ÿ”ฅThe 9th Round of Easy Loan, Earn $40 Reward is in progressโ—๏ธ โฐ Promotion Period: January 15th - Feburary 15th, 2025 ๐Ÿ‘‰ Register now and check more details at gate.io/campaigns/358
Kevin Fernando (@drkevinfernando) 's Twitter Profile Photo
Kevin Fernando
@drkevinfernando

4 years ago

Finally, I have updated my GPnotebook diabetes & renal shortcut to reflect new licenses/indications! Given complexity of the situation I have split original tool into 2 to reflect glycaemic & extra-glycaemic indicationd All feedback welcome! PDF download gpnotebookeducation.com

Finally, I have updated my <a href="/GPnotebook/">GPnotebook</a> diabetes &amp; renal shortcut to reflect new licenses/indications! Given complexity of the situation I have split original tool into 2 to reflect glycaemic &amp; extra-glycaemic indicationd All feedback welcome! PDF download gpnotebookeducation.com
CaReMeUK (@caremeuk) 's Twitter Profile Photo
CaReMeUK
@caremeuk

4 years ago

Encouraging data with SGLT2i continue to build in HFpEF. nature.com/articles/s4159โ€ฆ

Partha S Kar ๐Ÿ‡ฎ๐Ÿ‡ณ๐Ÿ‡ฌ๐Ÿ‡ง๐Ÿ๐ŸŽฅ (@parthaskar) 's Twitter Profile Photo
Partha S Kar ๐Ÿ‡ฎ๐Ÿ‡ณ๐Ÿ‡ฌ๐Ÿ‡ง๐Ÿ๐ŸŽฅ
@parthaskar

4 years ago

A short message to all with #Diabetes about the NICE guidelines released โ€œOr forever hold your peaceโ€ ๐Ÿ˜Š #gbdoc

CaReMeUK (@caremeuk) 's Twitter Profile Photo
CaReMeUK
@caremeuk

3 years ago

Updated NICE guideline on obesity published today. nice.org.uk/guidance/cg189โ€ฆ

Health Innovation Yorkshire & Humber CVD team (@cvdhealth_yh) 's Twitter Profile Photo
Health Innovation Yorkshire & Humber CVD team
@cvdhealth_yh

3 years ago

Are you working in Primary Care and have involvement in the referrals process to Lipid Clinics? We've created a survey to undertake a brief analysis of current referrals processes to Lipid Clinics in West Yorkshire. Help fill out our survey today: ow.ly/fakF50Kt3kZ

Are you working in Primary Care and have involvement in the referrals process to Lipid Clinics? We've created a survey to undertake a brief analysis of current referrals processes to Lipid Clinics in West Yorkshire. Help fill out our survey today: ow.ly/fakF50Kt3kZ
Eric Topol (@erictopol) 's Twitter Profile Photo
Eric Topol
@erictopol

2 years ago

Not every day you see an anti-obesity drug that has an average of >24% body weight loss ๐Ÿ†• NEJM #ADA2023 nejm.org/doi/full/10.10โ€ฆ Triple receptor agonist weight loss exceeds prior GLP-1 drugs (and dual receptor agents) and has yet to plateau

Not every day you see an anti-obesity drug that has an average of &gt;24% body weight loss ๐Ÿ†• <a href="/NEJM/">NEJM</a> #ADA2023 nejm.org/doi/full/10.10โ€ฆ Triple receptor agonist weight loss exceeds prior GLP-1 drugs (and dual receptor agents) and has yet to plateau
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo
Davide Capodanno
@dfcapodanno

2 years ago

Breaking news from Novo Nordisk. In the randomized, double-blind SELECT trial, semaglutide 2.4 mg as an adjunct to standard of care reduced MACE by 20% in 17,604 adults with established CVD with overweight or obesity and without prior history of diabetes. Let's wait for the NNT.

Breaking news from Novo Nordisk. In the randomized, double-blind SELECT trial, semaglutide 2.4 mg as an adjunct to standard of care reduced MACE by 20% in 17,604 adults with established CVD with overweight or obesity and without prior history of diabetes. Let's wait for the NNT.